TRIESENBERG, Liechte--(뉴스와이어)--The WHO has declared antibiotic resistances one of the Top 10 global threats to mankind. To counter this threat, Lysando AG has developed the so-called Artilysin® technology: Novel antimicrobial proteins with a unique mode of action.

The Artilysin® technology allows the Lysando team to design fit-for-purpose molecules by flexibly combining “modules” with antibacterial activity. In contrast to antibiotics Artilysin® also effectively attacks resistant and persistent - i.e., “dormant” - bacteria. Moreover, the technology - for example in topical applications - acts locally, does not breach the body‘s natural barriers or disrupt our skin’s natural defense system. The modular design allows a high degree of adaptation to diverse applications and indications.

Due to the particular mode of action of Artilysin® no receptors are required and harmful bacterial cells are mechanically eliminated within fractions of a second; a mechanism that explains the high resilience towards formation of resistances. In contrast, resistance to antibiotics is increasingly being identified even before their market entry.

“In 2019, bacterial infections represented the second leading cause of death worldwide - as concluded by an international study recently published in The Lancet. Owing to its novel mode of action, Artilysin® is a promising approach,” says Dr. Kerstin Emmrich, Head of Research and Development at Lysando AG.

For years, medical experts have been warning of the day that our “tools” against multi-resistant germs will no longer work. Artilysin® is a solution in the upcoming fight against resistance of pathogenic bacteria.

About Lysando AG

Lysando AG is the market leader for antimicrobial proteins, so-called Artilysin®s. They can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin®s constitute an innovative, proprietary and environmentally friendly technology with a wide range of applications: in human and veterinary medicine, but for example also in cosmetics.

Lysando AG‘s research facility is Lysando Innovations Lab GmbH located in Regensburg’s BioPark. BioPark Regensburg fosters companies in biotechnology, medical technology, diagnostics & analytics as well as the local healthcare management.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005034/en/